Get the Stockscreener App
135.81
2.45%
-3.59
Repligen Corp stock is traded at $135.81, with a volume of 124.90K.
It is down -2.45% in the last 24 hours and down -19.25% over the past month.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
See More
Previous Close:
$139.40
Open:
$138.88
24h Volume:
124.90K
Relative Volume:
0.18
Market Cap:
$7.63B
Revenue:
$633.51M
Net Income/Loss:
$-8.10M
P/E Ratio:
-438.10
EPS:
-0.31
Net Cash Flow:
$131.26M
1W Performance:
-2.63%
1M Performance:
-19.25%
6M Performance:
+12.01%
1Y Performance:
-6.68%
1-Day Range:
$133.50
$140.45
1-Week Range:
$133.50
$146.36
52-Week Range:
$102.97
$175.77
Repligen Corp Stock (RGEN) Company Profile
Name
Repligen Corp
Sector
Industry
Phone
(781) 449-9560
Address
41 SEYON STREET, WALTHAM, MA
Compare RGEN vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGEN
Repligen Corp
|
135.62 | 7.85B | 633.51M | -8.10M | 131.26M | -0.31 |
|
ISRG
Intuitive Surgical Inc
|
486.98 | 176.19B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
179.81 | 51.41B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
80.00 | 39.00B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
45.95 | 37.48B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
RMD
Resmed Inc
|
254.51 | 37.82B | 5.40B | 1.49B | 1.78B | 10.12 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-25 | Initiated | HSBC Securities | Buy |
| Sep-22-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-22-25 | Resumed | Stephens | Overweight |
| Jun-24-25 | Initiated | Barclays | Overweight |
| Apr-29-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | Evercore ISI | In-line |
| Feb-10-25 | Initiated | TD Cowen | Buy |
| Dec-17-24 | Initiated | Canaccord Genuity | Hold |
| Nov-14-24 | Initiated | Wolfe Research | Peer Perform |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-26-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jun-18-24 | Initiated | Guggenheim | Neutral |
| Dec-04-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-20-23 | Initiated | Wells Fargo | Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Mar-28-23 | Initiated | The Benchmark Company | Buy |
| Dec-14-22 | Initiated | Deutsche Bank | Hold |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-22 | Initiated | UBS | Buy |
| Oct-14-21 | Initiated | Exane BNP Paribas | Outperform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Aug-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-20 | Reiterated | H.C. Wainwright | Buy |
| May-07-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-23-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Nov-01-19 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Oct-15-19 | Initiated | SVB Leerink | Outperform |
| Aug-28-19 | Reiterated | First Analysis Sec | Outperform |
| Aug-23-19 | Resumed | Stephens | Overweight |
| Jul-22-19 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-17-18 | Upgrade | CL King | Neutral → Buy |
| Nov-12-18 | Downgrade | CL King | Buy → Neutral |
| Sep-26-18 | Initiated | H.C. Wainwright | Neutral |
| Dec-08-17 | Initiated | Citigroup | Buy |
| Dec-05-17 | Initiated | JP Morgan | Overweight |
| Nov-13-17 | Initiated | CL King | Buy |
| Oct-02-17 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
| Jul-21-17 | Initiated | William Blair | Outperform |
| Feb-13-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
View All
Repligen Corp Stock (RGEN) Latest News
Impax Asset Management Group plc Reduces Position in Repligen Corporation $RGEN - MarketBeat
Repligen to Report Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Bessemer Group Inc. Sells 238,450 Shares of Repligen Corporation $RGEN - Defense World
Repligen (NASDAQ:RGEN) Upgraded to "Buy" at Wall Street Zen - MarketBeat
What Makes Repligen Corporation (RGEN) an Investment Choice? - Yahoo Finance
Repligen is Now Oversold (RGEN) - Nasdaq
A Look At Repligen (RGEN) Valuation As Ordering Stabilizes And Growth Segments Progress - Yahoo Finance
Repligen Corp (RGEN) Stock Price Down 3.37% on Jan 29 - GuruFocus
Head-To-Head Comparison: Repligen (NASDAQ:RGEN) vs. Abpro (NASDAQ:ABP) - Defense World
3 Reasons to Sell RGEN and 1 Stock to Buy Instead - Finviz
Pharma News: Can Repligen Corporation navigate macro headwindsMarket Sentiment Review & Safe Entry Point Identification - mfd.ru
UBS Tags Repligen (RGEN) as Bioprocessing Leader for 2026, Cites 20% Order Growth and Reshoring Tailwinds - Insider Monkey
Repligen Corporation (NASDAQ:RGEN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Repligen Corp (RGEN) Shares Up 3.89% on Jan 21 - GuruFocus
Single-Use Bioprocessing Market Projected to Reach US$ 122.92 Billion by 2035, Supported by Expansion of Biomanufacturing Capacity Says Astute Analytica - GlobeNewswire Inc.
Slow Capital Inc. Has $5.89 Million Holdings in Repligen Corporation $RGEN - MarketBeat
Is It Too Late To Consider Buying Repligen Corporation (NASDAQ:RGEN)? - Yahoo Finance
Stephens Investment Management Group LLC Grows Stock Position in Repligen Corporation $RGEN - MarketBeat
Expert Outlook: Repligen Through The Eyes Of 5 Analysts - Benzinga
UBS raises Repligen stock price target to $200 on bioprocessing recovery - Investing.com
Why Repligen (RGEN) Shares Are Sliding Today - Finviz
Repligen Corp. Seeks M&A Opportunities - marketscreener.com
Published on: 2026-01-13 17:35:09 - Bộ Nội Vụ
Conestoga Capital Advisors LLC Has $127.91 Million Position in Repligen Corporation $RGEN - Defense World
Is Repligen Corporation stock gaining market share2025 Volatility Report & Growth Oriented Trading Recommendations - ulpravda.ru
Can Repligen Corporation stock hit record highs againJuly 2025 Levels & AI Powered Market Trend Analysis - Улправда
Repligen appoints Madaus as new board chair, Hunt to retire By Investing.com - Investing.com Canada
Repligen appoints Madaus as new board chair, Hunt to retire - Investing.com
Repligen Corporation Elects Dr. Martin D. Madaus as New Chair of the Board, Succeeding Tony Hunt - Quiver Quantitative
Repligen Corp Announces New Chair of the Board - TradingView — Track All Markets
Longtime Repligen leader steps down as new board chair takes over in 2026 - Stock Titan
Repligen Corporation (RGEN): Investor Outlook with a 15% Upside Potential in the Bioprocessing Sector - DirectorsTalk Interviews
Institution Moves: How risky is Repligen Corporation RGN stock compared to peersMarket Risk Report & Risk Controlled Stock Pick Alerts - Bộ Nội Vụ
About Us - FinancialContent
Pacer Advisors Inc. Has $1.37 Million Position in Repligen Corporation $RGEN - MarketBeat
Allspring Global Investments Holdings LLC Lowers Stake in Repligen Corporation $RGEN - MarketBeat
Bioprocess Filtration Global Markets Report 2025-2030, Profiles of Leading PlayersDanaher, Merck, Sartorius, Solventum, and RepligenResearchAndMarkets.com - Business Wire
Delta Investment Management LLC Buys Shares of 50,717 Repligen Corporation $RGEN - MarketBeat
Repligen Corporation (NASDAQ:RGEN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Why Repligen Corporation stock remains undervaluedFibonacci Retracement Levels & Free Dynamic Capital Growth - bollywoodhelpline.com
Is Repligen (RGEN) Quietly Recasting Its Gene Therapy Moat With New HiPer Viral Vector Resins? - simplywall.st
Riverbridge Partners LLC Sells 24,644 Shares of Repligen Corporation $RGEN - MarketBeat
Congress Asset Management Co. Boosts Stake in Repligen Corporation $RGEN - Defense World
Assenagon Asset Management S.A. Takes Position in Repligen Corporation $RGEN - MarketBeat
Can Repligen Corporation stock maintain growth trajectoryFed Meeting & Smart Allocation Stock Tips - Улправда
Texas Permanent School Fund Corp Has $3.13 Million Stock Holdings in Repligen Corporation $RGEN - MarketBeat
Will Repligen Corporation stock rally after Fed decisions2025 Winners & Losers & Free Technical Pattern Based Buy Signals - Улправда
Why Repligen Corporation (RGN) stock trades below fair valueJuly 2025 Drop Watch & Risk Managed Investment Signals - Bölüm Sonu Canavarı
Repligen (RGEN): Assessing Valuation After New Chromatography Resins Expand Its Gene Therapy Toolkit - simplywall.st
Repligen Corp Stock (RGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Repligen Corp Stock (RGEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MUIR GLENN P | Director |
Dec 16 '25 |
Option Exercise |
26.12 |
3,366 |
87,920 |
36,622 |
1.02%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):